Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
vision loss
Biotech
Gene editing biotech Graphite merges into vision loss biotech
Lenz is absorbing sickle-cell-focused Graphite Bio in a reverse merger that will see the combined company reemerge with a focus on vision loss.
Annalee Armstrong
Nov 15, 2023 9:57am
Astellas inks $6B Iveric buyout ahead of FDA eye disease ruling
May 1, 2023 8:13am
J&J links gene therapy to improved vision in early-phase trial
Oct 3, 2022 8:00am
Dry AMD developer LumiThera nets retina diagnostic maker Diopsys
Mar 4, 2022 10:40am
Editas claims proof of concept in vision loss gene-editing
Sep 29, 2021 9:00am
Novartis adds 2nd biotech to optogenetics gene therapy portfolio
Sep 21, 2021 1:15am
